Tissue distribution and elimination of [14C]apixaban in rats.
Apixaban, a potent and highly selective factor Xa inhibitor, is currently under development for treatment of arterial and venous thrombotic diseases. The distribution, metabolism, and elimination of [(14)C]apixaban were investigated in male, female, pregnant, and lactating rats after single oral doses. Tissue distribution of radioactivity in rats was measured using quantitative whole-body autoradiography. After a single oral administration, radioactivity distributed quickly in rats with C(max) at 1 h for most tissues. The elimination t(1/2) of radioactivity in blood was 1.7 to 4.2 h. The blood area under the plasma concentration-time curve of radioactivity was similar between male and female rats and was slightly higher in pregnant rats and lower in lactating rats. The radioactivity concentration in tissues involved in elimination was greater than that in blood with the highest concentration in the gastrointestinal tract, liver, and urinary bladder/contents and lowest level in brains. In pregnant rats, the whole-body autoradiogram showed that low levels of radioactivity were present in fetal blood, liver, and kidney and were much lower than the radioactivity in the respective maternal organs. The fecal route was the major pathway (74% of dose), and the urinary route was the minor pathway (14%) for apixaban elimination. After single oral doses of [(14)C]apixaban to lactating rats, apixaban exhibited extensive lacteal excretion with apixaban as the major component. In summary, tissue distribution of apixaban in rats was extensive but with limited transfer to fetal and brain tissues and extensive secretion into rat milk with the parent drug as the major component. Milk excretion could account for 10% of apixaban dose, which was comparable to urinary elimination in rats. Tissue distribution and drug excretion of apixaban are consistent with those for a moderately permeable drug that is a substrate for P-glycoprotein and breast cancer resistance protein efflux transporters.
Pharmaceutical Candidate Optimization , Bristol-Myers Squibb, P.O. Box 4000, Princeton, NJ 08543, USA.
Lifei
L
Wang
Kan
K
He
Brad
B
Maxwell
Scott J
SJ
Grossman
Larry M
LM
Tremaine
W Griffith
WG
Humphreys
Donglu
D
Zhang
D000284:Administration, Oral; D000818:Animals; D002250:Carbon Radioisotopes; D005243:Feces / Q000737:chemistry; D005260:Female; D005343:Fibrinolytic Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D008297:Male; D008431:Maternal-Fetal Exchange; D008657:Metabolic Clearance Rate; D008892:Milk / Q000737:chemistry; D011247:Pregnancy; D011720:Pyrazoles / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D011728:Pyridones / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution
D002250:Carbon Radioisotopes; D005343:Fibrinolytic Agents; D011720:Pyrazoles; D011728:Pyridones; C522181:apixaban